Building on PPMD's 10-Year-Old Duchenne Registry, the largest Patient Reported Outcomes Registry for the Disease, and Sarepta Therapeutics' Leadership with the First U.S.-Approved Therapy, New Interchange is Scheduled for 2019 Launch
PR Newswire
HACKENSACK, N.J. and CAMBRIDGE, Mass., Sept. 7, 2018